Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Recombinant human granulocyte colony-stimulating factor (G-CSF)]

Y Ariyoshi1

  • 1Dept. of Hematology and Chemotherapy, Aichi Cancer Center.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 1, 1993
PubMed
Summary

Recombinant granulocyte colony-stimulating factor (G-CSF) effectively reduces chemotherapy-induced neutropenia in cancer patients. This therapy shortens the duration of low white blood cell counts, improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy.

Cancer gene therapy·2016
Same author

The induction of antigen-specific CTL by in situ Ad-REIC gene therapy.

Gene therapy·2016
Same author

Disposition of TF-PEG-Liposome-BSH in tumor-bearing mice.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2009
Same author

Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2009
Same author

Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: a case report.

International journal of oral and maxillofacial surgery·2009
Same author

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

Annals of oncology : official journal of the European Society for Medical Oncology·2006

Area of Science:

  • Hematology
  • Oncology
  • Biotechnology

Background:

  • Colony-stimulating factors (CSFs) are crucial for hematopoietic progenitor cell development.
  • Granulocyte colony-stimulating factor (G-CSF) is a key stimulator of neutrophilic granulocyte production.
  • Recombinant G-CSF has transitioned from research to clinical application in cancer management.

Purpose of the Study:

  • To introduce recombinant G-CSF products for clinical use.
  • To evaluate the efficacy and safety of recombinant G-CSF in preventing chemotherapy-induced neutropenia.
  • To determine optimal dosing and administration for recombinant G-CSF therapy.

Main Methods:

  • Preclinical studies assessing G-CSF's stimulation of granulocyte production in myelosuppressed cancer patients.
  • Phase II clinical trials for the prevention of neutropenia following aggressive chemotherapy.
  • Evaluation of G-CSF toxicities and efficacy, including bone pain and headache.

Main Results:

  • Recombinant G-CSF demonstrated potential to stimulate granulocyte production in cancer patients experiencing chemotherapy-induced myelosuppression.
  • A subcutaneous dose of 2 micrograms/kg for 14 days post-chemotherapy was found to be optimal and acceptable.
  • Observed toxicities were generally manageable, including bone pain and headache.

Conclusions:

  • Recombinant G-CSF is a valuable therapeutic agent for mitigating chemotherapy-induced neutropenia.
  • The drug effectively reduces the nadir and duration of neutropenia in cancer patients.
  • Clinical use of recombinant G-CSF offers significant benefits in supportive cancer care.

Related Experiment Videos